Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Leukemia. 2024 Dec 3. doi: 10.1038/s41375-024-02487-1. Online ahead of print.
No abstract available

Publication types

  • Published Erratum